New England Biolabs is focused on the discovery and development of recombinant and native enzymes for genomic research. It offers restriction endonucleases for DNA digestion; PCR, polymerases, and amplification technologies for PCR applications; DNA modifying enzymes and cloning technologies; reagents for DNA and RNA sample preparation; DNA, RNA, and protein markers and ladders for electrophoresis applications; reagents for RNA research; and gene expression tools for DNA, RNA, and protein transfection of cell lines. The company also offers cellular analysis solutions; reagents, enzymes, antibodies, and DNA controls for epigenetics research; protein expression and purification technologies; competent cells for transformation and protein expression; protein tools; glycobiology products; and plasmids and DNAs for use in cloning experiments. New England Biolabs was founded in 1974 and is based in Ipswich, Massachusetts.

Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden.

Recombinetics is a developer of gene editing technologies to improve human health through advanced disease models and regenerative medicine. Its gene-editing technologies manipulate deoxyribonucleic acid (DNA) samples to add and activate genes to solve problems and also offer gene repair and gene editing tools that enable biomedical research, livestock productivity, animal agriculture, and livestock vertical markets to modify animal genomes accurately and efficiently.

A Premier Realestate Agency, Inc. (doing business as Aprea) is an American private company located in Springfield, NJ, that provides real estate services. David Michael Schwartz is currently the CEO of the firm.

PharmaGenics, Inc., part of Sanofi, is a company headquartered in Allendale, NJ. The firm develops therapeutic products for cancer. It was founded by Mike I. Sherman. PharmaGenics, Inc. was acquired by Genzyme Corp., now part of Sanofi on June 18, 1997 for $112 million.

Karolinska Institutet Innovations AB enables education, professional networking, funding, expertise in entrepreneurship and business development, and incubation opportunities for life science projects and companies. The company was founded in 1996 and is headquartered in Solna, Sweden.

The Eli and Edythe L. Broad Institute of MIT and Harvard (/ˈbroʊd/), often referred to as the Broad Institute, is a biomedical and genomic research center located in Cambridge, Massachusetts, United States. The institute is independently governed and supported as a 501(c)(3) nonprofit research organization under the name Broad Institute Inc., and is partners with Massachusetts Institute of Technology, Harvard University, and the five Harvard teaching hospitals.

As of January 6, 2009, Genelabs Technologies Inc. was acquired by SmithKline Beecham Corporation. Genelabs Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of infectious disease therapies to improve human health. The company's product pipeline consists of infectious disease projects focusing on Hepatitis C virus infection; and late-stage clinical assets, including an investigational vaccine for hepatitis E virus that is being developed by GlaxoSmithKline; and Prestara, an investigational drug for systemic lupus erythematosus. It has license and collaboration agreement with the Novartis Institutes for BioMedical Research for HCV polymerase non-nucleoside discovery research. Genelabs Technologies also has a collaborative research agreement with the National Health Research Institutes and Genovate Biotechnology Co., Ltd. to discover and develop compounds that target the hepatitis C virus. The company was founded in 1983 and is headquartered in Redwood City, California.

Warner-Lambert Co. used to manufacture and market pharmaceuticals, consumer health care products & confectionery. Its pharmaceutical products were ethical pharmaceuticals, biological products and hard-gelatin capsules. Its consumer health products were a wide range of products like oral care mouthwash/dental rinses, toothpaste, effervescent denture cleaning tablets, upper respiratory cold & sinus preparations, antihistamines, allergy products and cough syrups/suppressants. The company was headquartered in Morris Plains, NJ.

Marligen Biosciences is a privately held seller of DNA and RNA purification kits and multiplex assays for genotyping. Marligen Biosciences provides Vantage products that offer researchers a solution for microRNA analysis; Transcription Factor/Nuclear Receptor Products used in gene regulation; Signet Genotyping Assays, which are designed to detect genetic variations, including single nucleotide polymorphisms (SNP), small insertions and deletions, and whole gene deletions.

Applied StemCell Inc. (ASC) is a fast growing biotechnology company providing animal and cell line models as tools for drug discovery and diagnostics. Using our proprietary TARGATT™ gene modification technology, we make site-specific Knockin mouse, rat and human cell line models fast and efficient for pharmaceutical and academic community. Based on our Proprietary Technologies, we focus on the development and commercialization of: Mouse models (Knockin, Knockout, Transgenic, Site-specific transgenic - TARGATT™, Humanized mouse models) Rat models Human cell line model (Gene modified iPSC - adult stem cell / progenitor cells - differentiated cells) Stem cell culture products (optimized stem cell medium and reporters) Gene engineering in stem cells or other mammalian cells (e.g. generation of protein - production mammalian cell lines) We are striving to improve and expand our technologies and product lines to meet the increasing requirements of biomedical community. ASC welcomes your comments, suggestions and ideas.

Developer of a 3G sequencing technology using microscope. The company's platform technology addresses the major pain points in key areas of genomics research (what can be studied, the pace at which data can be understood, and the cost of discovery research) and thereby become a valued resource to the genomics industry, molecular diagnostics, and the future of personalized medicine.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

UAB Research Foundation (doing business as UABRF), a subsidiary of The University of Alabama System, is a company headquartered in Birmingham, AL. The firm engages in identify, assess, and market commercially viable technology developed at The University of Alabama at Birmingham.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Stratagene California is an American biotechnological company based in La Jolla, California, a maker of life science research and diagnostic products. It was established in 1984 and incorporated in California. It has been involved with the fields of cellular analysis, cloning, cytogenomics, DNA methylation and DNA Sizing and Quantification and food testing. In 2007, Agilent Technologies acquired Stratagene for $250 million, spinning off certain business assets and licensing certain molecular diagnostics technology to a new entity, Decisive Diagnostics. As of October 2011, the Chief Executive of the new company is Joseph Sorge, original founder and CEO of Stratagene.

Genex Corp. is an American private company located in Palatine, IL, that provides electrical services.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Nanjing Xinyihua Group Co., Ltd., established on 1999-12-09, Business scope includes genetic diagnosis technology,Various Gene Chips,Development of detection instrument system,Production;Hospital Consulting and Management;computer software development;aquaculture;Flowers and Nurseries,Construction and operation of environmental pollution control facilities;Sell ​​self-produced products;gene therapy drugs,Medical Diagnostic Reagents,Preparation of medical device projects(Not allowed to engage in business during the preparation period,Specific approval of business scope after obtaining relevant licenses).